Key Breast Cancer Abstracts in 2023 and Innovations in Ovarian Function Suppression:

Breast Cancer

Global Expert Perspectives

Video Library

Featuring:

Matteo Lambertini, MD, PhD
Associate Professor and Consultant in Medical Oncology
University of Genoa
Italy
Erica Stringer-Reasor, MD, Director
Breast Cancer Program
University of Alabama
O’Neal Comprehensive Cancer Center
Birmingham, Al
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, MA
Please join Sara Tolaney, MD, MPH, Dana-Farber Cancer Center, Boston, MA; Erica Stringer-Reasor, MD, University of Alabama, Birmingham; and Matteo Lambertini, MD, PhD, University of Genoa, Italy, as they provide expert commentary on key breast cancer abstracts presented at the 2023 ASCO Annual Meetings that will impact young women with ER+/HER2- breast cancer.

Related Items

Navigating the Complex Pathways to Clinical Trial Participation
By Jennifer Flores, MS; Marcela Orozco; Kelsey Hampton, PhD
Breast Cancer
May 2026 Vol 17, No 3
Clinical trials hold the promise of groundbreaking treatments, but the pathways to participation can be daunting. Learn how navigators are empowering patients to overcome barriers, ask the right questions, and confidently explore life-changing opportunities.
Supporting Young Patients With Breast Cancer
By Zeena Nackerdien, PhD
Breast Cancer
December 2025 Vol 16, No 12
Explore the unique challenges faced by young patients with breast cancer and learn how innovative navigation programs are bridging gaps in care and empowering patients to thrive.
Identification and Treatment of Patients With Hormone Receptor–Positive, HER2-Negative Early Breast Cancer at High Risk of Recurrence: monarchE Study Long-Term Outcomes
Clinical Trials, HR+/HER2− Breast Cancer, Breast Cancer
Special Issues and Supplements
We are pleased to announce the release of our next issue of Clinical Trials to Clinical Practice. This article provides expert commentary from Joyce A. O’Shaughnessy, MD, on the use of endocrine therapy with or without adjuvant abemaciclib for patients with high-risk, hormone receptor (HR)-positive, HER2-negative early breast cancer.
Journal of Oncology Navigation & Survivorship

Contact Us | Editorial Board

Amplity

© Amplity, Inc. All rights reserved.

Connect with Us

 
 
JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country

Back to Top

Amplity © Amplity, Inc. All rights reserved.